Skip to main content
. 2020 Jul 22;11:796. doi: 10.3389/fgene.2020.00796

FIGURE 9.

FIGURE 9

The AS-clinicopathologic nomogram for prediction on survival probability in patients with ESCA. (A) Development of AS-clinicopathologic nomogram for predicting 1-, 3-, and 5-years OS for ESCA patients. (B–D) Calibration plot of the AS-clinicopathologic nomogram in terms of agreement between nomogram-predicted and observed 1-, 3-, and 5-years outcomes in the ESCA cohort. The actual performances of our model are shown in red lines. And the silver line of 45° represents the ideal performance. (E–G) Decision curve analyses of the AS-clinicopathologic nomogram for 1-, 3-, and 5-years risk in ESCA cohort. The gray line represents the net benefit of treat-all scheme varying with threshold probability, while the black line represents the net benefit of treat-no scheme. The net benefits by using our nomogram for predicting 1-, 3-, and 5-years OS are displayed with imaginary line.